scholarly journals Effect of Lactobacillus rhamnosus on Intestinal Mucosal Barrier Function in Mice with Post-Infectious Irritable Bowel Syndrome

2020 ◽  
Vol 82 (6) ◽  
Author(s):  
YING CHANG ◽  
JIE MENG ◽  
Q. DI ◽  
S. LOU ◽  
XINLI FENG ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Barrier Function ◽  
Lactobacillus Rhamnosus ◽  
Mucosal Barrier ◽  
Intestinal Mucosal Barrier ◽  
Mucosal Barrier Function ◽  
Irritable Bowel ◽  
Post Infectious

scholarly journals Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

2021 ◽  
pp. 144-150
Author(s):  
E. Yu. Plotnikova
Keyword(s):  
Irritable Bowel Syndrome ◽  
Barrier Function ◽  
Adult Population ◽  
Bifidobacterium Longum ◽  
Intestinal Flora ◽  
Visceral Hypersensitivity ◽  
Mucosal Barrier ◽  
Abdominal Symptoms ◽  
Mucosal Barrier Function ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal disorders affecting between 5 and 15% of the general adult population worldwide. Over the course of many years altered intestinal motility, visceral hypersensitivity, immune changes and, as it has recently been found, impaired epithelial barrier function were meant to explain the origin of symptoms in the IBS. We have come to realize now that the IBS warrants serious clinical and scientific study. Not that long ago, the connections between the gut and the brain have been expanded to include a new entrant, the microbiota, resulting in the creation of a new concept of a microbiota-gut-brain axis.Microbiota is a risk factor for the irritable bowel syndrome. Probiotics are defined as live microorganisms, which can alter the intestinal flora and regulate intestinal functions such as reduction of visceral hypersensitivity, improvement of mucosal barrier function, modulate immune responses and chronic inflammation, affect the central nervous system, gastrointestinal motility, etc. The correctness of this approach is confirmed by several studies of the probiotic Bifidobacterium longum subsp. longum 35624, which is widely used in the treatment of symptoms of irritable bowel syndrome. The dietary supplement Bifidobacterium longum subsp. longum 35624 contains 1 × 109 colony-forming units, which provides a clinically effective level of these beneficial bacteria. Bifidobacterium longum subsp. longum 35624 also reduces inflammation in the gastrointestinal tract and has positive results in reducing abdominal symptoms (e.g. abdominal pain / discomfort and bloating) associated with the irritable bowel syndrome and other conditions. 

Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats

2018 ◽  
Vol 22 (6) ◽  
pp. 731-738 ◽  
Author(s):  
Weiying Ren ◽  
Jiayu Wu ◽  
Li Li ◽  
Y. Lu ◽  
Y. Shao ◽  
...  
Keyword(s):  
Barrier Function ◽  
Mucosal Barrier ◽  
Aged Rats ◽  
Intestinal Mucosal Barrier ◽  
Mucosal Barrier Function ◽  
Glucagon Like Peptide

scholarly journals Protective effect and mechanism of fucoidan on intestinal mucosal barrier function in NOD mice

2020 ◽  
Vol 31 (1) ◽  
pp. 939-953
Author(s):  
Ting Sun ◽  
Hui Liang ◽  
Meilan Xue ◽  
Ying Liu ◽  
Anjing Gong ◽  
...  
Keyword(s):  
Protective Effect ◽  
Barrier Function ◽  
Nod Mice ◽  
Mucosal Barrier ◽  
Intestinal Mucosal Barrier ◽  
Mucosal Barrier Function

scholarly journals N-acetyl glucosamine improves intestinal mucosal barrier function in rat

2012 ◽  
Vol 7 (4) ◽  
Author(s):  
Yanxia Liu ◽  
Weiwei Xu ◽  
Lei Liu ◽  
Linming Guo ◽  
Yu Deng ◽  
...  
Keyword(s):  
Barrier Function ◽  
Mucosal Barrier ◽  
Intestinal Mucosal Barrier ◽  
Mucosal Barrier Function
Sign in / Sign up

Export Citation Format

Share Document